

9th Paris Hepatitis Conference, January 11-12, 2016

Follow-up of patients with SVR

Lawrence Serfaty Service d'Hépatologie, UMR_S 938 Hôpital Saint-Antoine Université Pierre&Marie Curie Paris, France



Circulation, IIII Inserm


French Institute of Health and Medical Research

Disclosures

- Consulting, advisory committees or review panel
 - Abbvie, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Janssen, Merck Sharp & Dohme, Roche
- Speaking and teaching
 - Abbvie, Aptalis, Bristol-Myers
 Squibb, Gilead, Janssen, Merck Sharp &
 Dohme, Roche



New all-oral regimens are transforming the HCV treatment landscape




n patients with HCV genotype 1 only; ** In treatment-naïve patients; ‡Includes treatment-naïve and -experienced patients

BOC, boceprevir; IFN, interferon; RBV, ribavirin; SVR, sustained virologic response; TVR, telaprevir 1. Adapted from Manns MP, et al. *Gut* 2006;55:1350–9. 2. Tran TT. *Am J Manag Care* 2012;18(14 Suppl.):S340–9. 3. Goralczyk AD, et al. BMC *Gastroenterology* 2013;13:148. 4. Feld JJ, et al. *N Engl J Med*. 2014;370:1594-603. 5. Sulkowski M, et al. *N Engl J Med*. 2014;370(3):211-21. 6. Afdhal N, et al. *N Engl J Med*. 2014;370:1889–98. 7. Afdhal N, et al. *N Engl J Med*. 2014;370:1483-93.



SVR is associated with improvement of survival (meta-analysis n=34 563)



Effect of SVR on death



Simmons B, et al. Clin Infec Dis 2015

Liver-related morbidity/mortality in SVR patients

Long term fibrosis outcome in SVR patients

Predictors of liver disease outcome in SVR patients: the role of comorbidities

Monitoring of SVR patients: the value of non invasive markers



Liver-related morbidity/mortality in SVR patients


Long term fibrosis outcome in SVR patients

Predictors of liver disease outcome in SVR patients: the role of comorbidities

Monitoring of SVR patients: the value of non invasive markers



779 patients treated with sofosbuvir-containing regimen



Yoshida EM, et al. Hepatology 2015

Long term follow-up studies in DAAs-related SVR patients are ongoing.


Persitence of occult HCV infection ?

Radkowski M, et al. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 2005; 41: 106–14. Castillo Let al Hepatitis C virus replicates in the liver of sustained responder patients to Long technic reaction in School 100; 43 Utive to regimen?



Risk of reinfection following SVR (meta-analysis n=34 563)

5 yrs risk of reinfection post SVR



EASL guidelines

Following SVR, monitoring for HCV reinfection through annual HCV RNA assessment should be undertaken in people who inject drugs or men who have sex with men with on-going risk behaviour (B2)

Hill AM, et al. AASLD 2014



Plan

The durability of SVR with DAAs regimens

Liver-related morbidity/mortality in SVR patients


Long term fibrosis outcome in SVR patients

Predictors of liver disease outcome in SVR patients: the role of comorbidities

Monitoring of SVR patients: the value of non invasive markers



The risk of liver transplantation or HCC according to SVR (meta-analysis n=34 563)






Simmons B, et al. Clin Infec Dis 2015

Excess liver-related morbidity following discharge of SVR patients

1215 HCV patients treated between 1996-2007, follow-up 5.3 yrs






Innes HA, et al. Hepatology 2011

Risk of HCC in non cirrhotic patients following HCV eradication

642 SVR patients followed 53 mo: 86 cirrhotics, 556 non-cirrhotics





Huang CF, et al. J Hepatol 2014

Liver-related morbidity/mortality in SVR patients


Long term fibrosis outcome in SVR patients

Predictors of liver disease outcome in SVR patients: the role of comorbidities

Monitoring of SVR patients: the value of non invasive markers




Regression of fibrosis in SVR patients is slow





Regression of fibrosis in SVR patients is slow

97 SVR patients with paired LB, 5.8 yrs






Tachi Y, et al. Hepatol Res 2015; 45: 238–46.

Long term fibrosis outcomes in SVR patients according to non invasive markers

933 HCV patients with paired Fibrotest™, median FU 5.3 yrs





Poynard T, et al. J Hepatol 2013

Plan

The durability of SVR with DAAs regimens

Liver-related morbidity/mortality in SVR patients

Long term fibrosis outcome in SVR patients


Predictors of liver disease outcome in SVR patients: the role of comorbidities

Monitoring of SVR patients: the value of non invasive markers



Overweight is a risk factor of cirrhosis occurrence in SVR patients

German HCV (1b)-contaminated anti-D cohort: Clinical outcome after 35 yrs follow-up



Overall survival was significantly enhanced after SVR, compared to treatment-naïve patients or non-SVR (p=0.027)

Independent factors associated with cirrhosis

- No response to treatment
- No spontaneous recovery
- BMI >25 kg/m2 (RR: 1.125)




Wiese M, et al. Hepatology 2014 ;59:49–57.

Risk factors of HCC following SVR

	SVR patients	Follow-up (yrs)	Risk factors
Chang 2012	871	3.4	-Age -Fibrosis -Post SVR AFP
Arase 2013	1751	8.1	-Age -Male -Alcohol -Diabetes
Oze 2014	1425	3.3	-Age -Post SVR AFP
Yamashita 2014	562	4.8	-Age -Fibrosis -Alcohol -Post SVR AFP
Huang 2014	642	4.4	-Age -Fibrosis - <mark>Diabetes</mark>
Chang 2015	801	5.0	-Age -Fibrosis -Post SVR AFP

Metabolic syndrome and risk of HCC in SVR cirrhotic patients






Risk factors of HCC following SVR in non cirrhotic patients

556 non-cirrhotic patients with SVR

Predictive factors of HCC : age, GGT, type 2 diabetes and APRI






Huang CF, et al. J Hepatol 2014

Predictive score of HCC occurrence in cirrhotic patients




Independent predictors: Age>50yrs, Alcohol, GGT>N, platelets, SVR

Score ≤ 5 : low risk; 6 -10 : moderate risk; 11-14: high risk; > 14: very high risk



CirVir ANRS CO12 AFEF/ILCA 2015

Progression of fibrosis is associated with HCC occurrence in SVR patients








Tachi Y, et al.. Hepatol Res 2015; 45: 238–46.

Reversion of cirrhosis and clinical outcome





Mallet L, et al. Ann Intern Med 2008;149:399–403

Liver-related morbidity/mortality in SVR patients


Long term fibrosis outcome in SVR patients

Predictors of liver disease outcome in SVR patients: the role of comorbidities

Monitoring of SVR patients: the value of non invasive markers



Difference between biopsy and FibroTest® estimates of fibrosis progression in treated patients






Poynard T, et al. Antivir Ther 2010

Accuracy of APRI, FIB-4 and Forns index at post-SVR for predicting fibrosis in the second liver biopsy


115 SVR patients with control liver biopsy at 5 yrs

Differentiation of moderate to advanced fibrosis (F2-4) from mild fibrosis (F0-1)




ROC>0.8 Accuracy>70%

Differentiation of advanced fibrosis (F3–4) from mild to moderate fibrosis (F0-2)



Tachi Y, et al. PloS One 2015

Accuracy of fibroscan following SVR



33 biopsy-proven cirrhotic CHC patients with SVR Liver biopsy + LSM 61 (48-104) months after SVR


	F0-3	F4
TE <12 kPa	19	5
TE ≥12 kPa	1	8



D'Ambrosino R, et al. J Hepatol 2013

Liver stiffness and antiviral treatment: lower cut-off for cirrhosis diagnosis?








Courtesy by J Boursier

Take-Home Message

- After the cure of HCV infection, regression of fibrosis varies and the risk of liver-related complications remains, even in the absence of cirrhosis.
- Comorbidities such as diabetes, obesity or alcohol consumption can play a major role in the outcome of liver disease in SVR patients and should be managed.
- Although not currently recommended in guidelines, noninvasive tests could be useful for assessing the outcome of fibrosis in SVR patients without cirrhosis.
- Screening for HCC after HCV cure is recommended in patients with extensive fibrosis.





NIT: non invasive test

